The management of type 2 diabetes (T2D) and obesity has been revolutionised by glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (e.g., dulaglutide, liraglutide, semaglutide), and, more recently, dual agonists of GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP) receptors, such as tirzepatide. Here, GLP1R is linked to obesity disorder.